Published: March 2023 | Report Code: 12555 | Available Format: PDF
The lung cancer surgery market size stood at USD 5.65 billion in 2022, and it is expected to grow at a CAGR of 4.10% during 2022–2030, to reach USD 7.79 billion by 2030. The growth can be primarily attributed to the rising incidence of lung cancers, extensive tobacco smoking trend among youngsters, rising geriatric population, and availability of reimbursements.
Moreover, the growing emphasis on the early diagnosis and treatment of this condition, growing adoption of minimally invasive procedures as well as robotic surgeries, and rising pace of technological advancement in the associated surgeries will propel the growth of the market during the forecast period.
Lung cancer is among the most-common causes of cancer death among the global population. Its incidence and mortality rate are increasing significantly due to the trend of smoking in almost every age group around the world. Lung cancer, which mainly includes tracheal and bronchial cancers, is considered a threat to individuals globally, resulting in a heavy emotional and financial burden on people and their families. According to the GLOBOCAN, worldwide, lung cancer is the most-prevalent malignancy, with an age-standardized rate of 22.4 per 100,000 person-years. Generally, men have a greater risk of this condition than women. The incidence rate in men was 222.0 and that in women was 186.0 in the year 2020. The rising incidence is driving the demand for surgeries and, in turn, the market.
The thoracotomy category accounted for the larger revenue share, of over 62%, in 2022. The thoracotomy category is further divided into lobectomy, sleeve resection, segmentectomy, and pneumonectomy. The growth of the thoracotomy category is majorly attributed to the rising number of such surgeries on lung cancer patients. Surgery is an effective treatment when the tumor is diagnosed before spreading. According to the Journal of Thoracic Disease (JTD), an estimated 222,520 surgical operations for lung cancer are conducted every year. Among the various types of thoracic surgeries, the most common is the lobectomy, which accounts for 68.2% of those conducted, followed by wedge resection, which occupies a share of 18.1%.
Furthermore, the adoption of powered surgical instruments, which offer speedier procedures with their excellent functionality and dependable performance compared to manual equipment, is rising. In addition to that, lung cancer surgeries require high device flexibility and usability, which are provided by the advanced instruments. In order to meet the growing demand for them, the key players are focusing on launching new technologies.
For instance, in May 2021, Olympus Corporation launched the FDA 510(k)-cleared endobronchial ultrasound (EBUS) bronchoscope BF-UC190F, which is the latest addition to its EBUS portfolio of devices for minimally invasive lung cancer detection and staging by needle biopsy. This launch allows the surgeon to reach and sample complex sites, such as the lymph nodes in the mediastinum (4L) and hilum (10R). Thus, the device provides a higher diagnostic yield with greater sensitivity and specificity in lymph nodes ≥5 mm.
Moreover, the minimally invasive surgery category is expected to grow at the higher rate during the forecast period, owing to the increasing usage of these procedures, advancement in their technologies, favorable reimbursement regulations, and growing trend of robot-assisted surgical operations.
The surgical instruments category is expected to grow at the highest rate, of 4.6%, in the market for lung cancer surgeries during the forecast period, based on surgical devices. This can be ascribed to the rising volume of surgeries for lung cancer due to its high incidence and the government support and funding for the same. In addition to that, the advances in surgical instruments considerably increase their versatility and simplify their usage during complex operations.
Moreover, the advent of the powered and tissue-specific endoscopic stapling technology, which offers the advantage of better resource usage, lower cost, and improved clinical outcomes over manual staplers, has revolutionized the field. For instance, in September 2022, Ethicon, a part of Johnson & Johnson Medical Devices Companies, launched the Echelon Circular powered circular surgical stapler for thoracic, colorectal, and gastric surgeries. This stapler enables even compression with its 3D Stapling Technology and allows for gentle handling with its Gripping Surface Technology (GST), both of which work together to minimize the compressive forces on the tissues.
Moreover, in December 2021, the FDA approved Intuitive’s fully wristed, 8-mm SureForm 30 curved-tip stapler and reloads for general, thoracic, urologic, gynecologic, and pediatric surgeries. With 120-degree articulation, a curved tip, and the SmartFire technology, this stapler enables surgeons to better see and address patient anatomy from various angles, as it fits through the 8-mm instrument cannula of the da Vinci surgical system.
Market Size in 2022
USD 5.65 Billion
Revenue Forecast in 2030
USD 7.79 Billion
Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling
By Product Type; By Surgical Procedure; By End User; By Region
Explore more about this report - Request free sample
North America led the market, with a revenue share of 38%, in 2022, owing to the increasing pace of technological advancements in the treatment of lung cancer, growing incidence of this disease in the region, booming trend of tobacco smoking, and surging emphasis on its early screening.
The U.S. market is expected to register the larger revenue share in the North American region, due to the high prevalence of lung tumors, advanced facilities, high awareness regarding the treatment, and high spending by the government and private sector on the advancement of the healthcare expenditure of the country. As per the Lung Cancer Research Foundation, in 2022, approximately 236,740 individuals had lung cancer in the U.S., and 130,180 deaths occurred due to it.
Additionally, market players are focusing in manufacturing better products with the help of various collaborations and acquisitions with regional players and third-party CDMO service providers.
The Asia-Pacific region is expected to witness the fastest growth during the forecast period. This will mainly be due to the rapid enhancement in the healthcare infrastructure of the region, increasing government funding and awareness-raising initiatives, and growing medical tourism industry in emerging economies, such as India and China.
The cancer hospitals category accounts for the largest revenue share based on end user, which is mainly due to the growing prevalence of lung cancer. Among all the end users, such as hospitals, ambulatory surgery centers, and research laboratories, hospitals are the preferred medical settings, as they have the most-advanced equipment for precise diagnosis and treatment. This is why the standard of care provided by hospitals is higher, supported by the high public and private funding.
Furthermore, ambulatory surgery centers are expected to register a moderately high revenue growth rate. ASCs are modern healthcare clinics that are focused on offering same-day surgical care, in addition to diagnostic and preventive procedures. Nowadays, patients are preferring these surgical centers as they do not require hospitalization, and patients can return home shortly after the operation.
Moreover, the flourishing number of such centers, increasing adoption of minimally invasive procedures, cost-effectiveness of the treatments provided by them compared to hospitals, and growing trend of outpatient facilities will fuel the growth of the category over the forecast period.
The introduction of robot-assisted thoracic surgery systems is providing lucrative opportunities to the market for lung cancer surgeries. Nowadays, robotic thoracic surgeries are highly preferred over the conventional, open ones due to the higher precision and magnification offered by surgical robots, which also eliminate the need for large incisions. The development of new surgical equipment, along with the advent of improved imaging techniques, is contributing to the growth of the market. This cuts the expense on surgical devices and enhances visualization by angled lenses, for improved accessibility.
In February 2020, Temple University Hospital began offering a robotic minimally invasive tool, the Ion endoluminal system, for the bronchoscopic biopsy of the lung, in combination with Philips cone-beam CT and augmented fluoroscopy for lung nodule biopsy. The Ion system offers increased mobility and navigation through narrow airways to nodules located deep in the peripheral lung.
Several more market players are emphasizing the development of new robot-assisted thoracic surgery systems, by collaborating or partnering with superior surgical device and visualization technology vendors. For instance, in September 2021, Medtronic launched its new robotic surgery platform, Hugo RAS system, in India. This modular, multi-quadrant platform enables surgeons and other members of the operating room staff to perform a broad range of soft-tissue procedures with more proficiency.
This fully customizable report gives a detailed analysis of the lung cancer surgery market from 2017 to 2030, based on all the relevant segments and geographies.
Based on Surgical Procedure
Based on Product Type
Based on End User
The 2022 size of the market for lung cancer surgeries was USD 5.65 billion.
Thoracotomies are preferred in the lung cancer surgery industry.
APAC will be the fastest-growing market for lung cancer surgeries.
Robot-assisted surgeries are the biggest opportunity in the lung cancer surgery industry.
Cancer hospitals hold the largest share in the market for lung cancer surgeries.
Get a bespoke market intelligence solution
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws